{"entity":{"id":"nct07718243","kind":"trial","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","aka":["BLAZE"],"tldr":"A phase 1/2 trial in lung cancer, run by Institute of Cancer Research, United Kingdom, now recruiting.","summary":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC is a phase 1/2, interventional study registered as NCT07718243 by Institute of Cancer Research, United Kingdom, with a registry enrolment figure of 62 participants, started 2026-08-28 and due to reach its primary completion in 2030-01-31. Interventions recorded: Bexmarilimab 1mg/kg and nivolumab 1mg/kg; Bexmarilimab 3mg/kg and nivolumab 1mg/kg; Recommended Phase II Dose. Conditions listed: Melanoma (Skin Cancer); Non Small Cell Lung Cancer; Solid Tumor in Advanced Stage. Primary outcome: To establish a recommended Phase II dose (RP2D) of bexmarilimab in combination with nivolumab; Determining causality of each adverse event to bexmarilimab and nivolumab and grading severity according to the NCI CTCAE Version 5.0; Evaluation of disease response by RECIST criteria version 1.1, immune-. Lung eligibility wording from the registry: \"Part B1: Histologically proven NSCLC\". Sites: United Kingdom. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07718243","url":"https://clinicaltrials.gov/study/NCT07718243"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["faron-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): The Christie NHS Foundation Trust (Manchester); The Royal Marsden NHS Foundation Trust - Drug Development Unit (Sutton)."],"nct":"NCT07718243","phase":"1/2","setting":"A Phase I/II Trial of Bexmarilimab and Nivolumab in Patients With Solid Tumours, Non-Small Cell Lung Cancer and Melanoma","sponsor":"Institute of Cancer Research, United Kingdom","enrolled":62,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07718243/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}